A Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Anti-Inflammatory Compound Anatabine to Treat Pain in GWI Patients

Abstract

The goal of this clinical trial is to target one of the major complaints from veterans with Gulf War Illness (GWI) - namely chronic pain and inflammation - with a compound that has a history of safe use in humans and is shown to be effective in animal models of exposure to agents known to have caused GWI. Chronic musculoskeletal pain and associated inflammation are some of the most debilitating symptoms of GWI. Identifying effective, safe, and tolerable treatments will alleviate major aspects of the multisymptom condition that as yet has not effective treatment. In a recent presentation of data from the national War Related Illness and Injury Study Centers (WRIISC) in California, New Jersey and Washington DC, the reported major complaints of veterans, and specifically of GW veterans, was pain (90 ), exceeding the next most prevalent symptom, fatigue, by three fold.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1027673

Entities

People

  • Fiona Crawford

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Clinical Trials
  • Communities
  • Department Of Defense
  • Dietary Supplements
  • Diseases And Disorders
  • Governments
  • Institutional Review Board
  • Local Governments
  • Medical Personnel
  • Muscular Diseases
  • Pain
  • Patent Applications
  • Persian Gulf Syndrome
  • Professional Development
  • Training

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.